	Anningsion No	Applicant(a)
	Application No.	Applicant(s)
Notice of Allowability	10/666,095	HAMMER ET AL.
	Examiner	Art Unit
	Jeffrey E. Russel	1654
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to the response filed September 17, 2007.		
2. The allowed claim(s) is/are 1,4,7-18,20,21,51-53,55 and 57-60.		
<ul> <li>3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) ☐ All b) ☐ Some* c) ☐ None of the:</li> <li>1. ☐ Certified copies of the priority documents have been received.</li> </ul>		
Certified copies of the priority documents have been received.      Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in Application No		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1)  hereto or 2)  to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
<ol> <li>DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.</li> </ol>		
		•
Attachment(s)  1. Notice of References Cited (PTO-892)	5. Notice of Informal F	Patent Application
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary	• •
	Paper No./Mail Da	te
<ol> <li>Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date</li> </ol>	7. Examiner's Amend	
Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. 🛛 Examiner's Stateme	ent of Reasons for Allowance
5	9.  Other	

Application/Control Number: 10/666,095

Art Unit: 1654

1. The Sequence Listing filed September 17, 2007 is approved.

The following is an examiner's statement of reasons for allowance: The claimed 2. invention is deemed allowable over the prior art of record or any combination thereof. With respect to instant claim 57, the claim is entitled under 35 U.S.C. 119(e) to the benefit of the filing date of provisional application 60/412,081, and therefore the Fu dissertation and the Aucoin oral presentation are not prior art under 35 U.S.C. 102 against the claim. With respect to the Fu et al article (Organic Letters, Vol. 4, pages 237-240) and its disclosure of the peptide recited in instant claim 57, the declaration by Hammer filed September 17, 2007 shows that the peptide was not "by others", and the Fu et al article's disclosure of the peptide is therefore not available as prior art against the claim under 35 U.S.C. 102(a). With respect to instant claims 58 and 60, the Fu dissertation's disclosure of the peptide which it designates "AMY-2" is not prior art under 35 U.S.C. 102(a) against the claims, because the Hammer declaration filed September 17, 2007 shows that the peptide is not "by others". With respect to instant claims 58 and 59, the Aucoin oral presentation's disclosure of the peptide which it designates "AMY-3" is not prior art under 35 U.S.C. 102(a) against the claims, because the Hammer declaration filed September 17, 2007 shows that the peptide is not "by others".

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Art Unit: 1654

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey E. Russel at telephone number (571) 272-0969. The examiner can normally be reached on Monday-Thursday from 8:00 A.M. to 5:30 P.M. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor Cecilia Tsang can be reached at (571) 272-0562. The fax number for formal communications to be entered into the record is (571) 273-8300; for informal communications such as proposed amendments, the fax number (571) 273-0969 can be used. The telephone number for the Technology Center 1600 receptionist is (571) 272-1600.

Jeffrey E. Russel

Primary Patent Examiner

Art Unit 1654

**JRussel** 

October 24, 2007